Dual-payload ADC

In one sentence

A dual-payload ADC carries two different drugs on one antibody, betting that a tumor cell is far less likely to survive two mechanisms delivered together than either one alone.

The intuition

A burglar who can pick one kind of lock is stopped by a door with two different locks. A cancer cell that has learned to pump out one drug, or to repair one kind of damage, still has to beat a second, unrelated attack arriving at the same moment. The analogy breaks in one place: the second lock also makes the door heavier. Every extra drug adds its own side effects.

How it works

An antibody-drug conjugate (ADC) normally carries many copies of one payload. A dual-payload ADC attaches two payload types to the same antibody, each at a set number of copies. One design route uses chemically distinct attachment sites so the ratio is the same on every molecule; see ADC conjugation chemistry.

Designs make one of two biological bets:

Both drugs reach the same cell at the same moment and at a fixed ratio. That is the difference from giving two drugs separately.

Why put both drugs on one antibody instead of giving two drugs? Three reasons follow from the biology:

1. Same cell. Two separate ADCs reach different cells unevenly. In mice with breast tumors that mixed high- and low-HER2 cells, a HER2 ADC carrying two payloads worked better and prolonged survival more than the same two payloads given together on two separate ADCs [1]. Both payloads in that study were tubulin drugs (MMAE and MMAF) that differ in how far they spread, so it tests same-cell delivery, not the TOP1-plus-tubulin pairing.
2. Same time. Synergy between DNA damage and a blocked damage alarm depends on timing: the alarm must be off while the damage is happening.
3. Lower doses elsewhere. DNA-damage-response inhibitors given as pills with chemotherapy have been limited by blood-count toxicity. Delivering the chemotherapy through an antibody is one way around that. A phase 1 trial combined the TOP1 ADC sacituzumab govitecan with the ATR inhibitor berzosertib in 12 people and found no dose-limiting toxicities, which the authors contrasted with earlier chemotherapy combinations [2]. That trial gave the ATR inhibitor separately; a dual-payload ADC takes the next step of putting both on one antibody.

The synergy itself is well established in cells. In a screen of nearly 7,000 genes, losing ATR was among the top ways to make cells more sensitive to a TOP1 inhibitor; an ATR inhibitor reproduced the effect [3]. A TROP2 antibody carrying the TOP1 payload exatecan was likewise synergistic with ATR inhibitors in pancreatic cancer cells [4].

Why it matters in cancer

• Every ADC approved for triple-negative breast cancer carries a TOP1 payload, and resistance to one TOP1 ADC can carry over to the next; see cross-resistance between ADCs. A second payload class on the same antibody is one direct answer to that problem.
• Tumor heterogeneity means one tumor can hold cells that resist in different ways. Two mechanisms raise the odds that each cell meets a drug it cannot handle.
• No dual-payload ADC is approved [5]. First trials in people are registered, for example IBI3028, a dual-payload conjugate on an antibody aimed at both EGFR and c-MET, in a phase 1 trial in advanced solid tumors [6]. No efficacy results in breast cancer have been published.

Common confusions

• A dual-payload ADC is not a combination regimen. In a combination, each drug's dose can be changed separately. Here the ratio is fixed when the drug is made, so if one payload causes the dose-limiting side effect, the other comes down with it.
• Two payloads are not automatically twice as good. The two drugs differ in potency; the more potent one can set the dose and leave the other below the level where it helps.
• A dual-payload ADC is not a bispecific ADC. A bispecific ADC has two targets and usually one payload; a dual-payload ADC has two payloads and usually one target. Some products combine both.
• Better results in mice do not show the second drug helps people. Proving it requires comparing against the same antibody with one payload.

What could break the bet

• Toxicity adds up. A TOP1 payload brings low blood counts and diarrhea; MMAE brings nerve damage; ATR inhibitors lower blood counts on their own. See ADC payload toxicities.
• The ratio may be wrong for most tumors. The best ratio of the two drugs is a guess made at manufacture, and the ratio reaching a tumor can change if one payload falls off the antibody faster.
• Measuring is harder. Developers must track the antibody, two free payloads and more possible immune reactions against the drug [5].
• The shared step still fails. If the cancer stops displaying the target, or stops taking the antibody in, both payloads fail together.

How it is measured

The decisive test is a comparison against the matching single-payload ADC, in the laboratory and then in people: a dual-payload ADC should kill cells, or control tumors, that the single-payload version cannot. In trials, the key questions are responses in people whose cancer already grew on a TOP1 ADC, and whether the dose of each payload stays effective once side effects are accounted for.

In Diana's case

How this applies to her is owned by the drug-panel preferences page.

Related concepts

• ADC payload classes
• DNA-damage-response inhibitor payloads
• Next-generation TOP1 payloads
• DNA-damage-response inhibitors
• Synthetic lethality
• Replication stress
• Read a new payload strategy

Sources and scope

Source check: November 7, 2026. Mechanism, laboratory evidence and early trial registrations; no dual-payload ADC has human efficacy results in breast cancer. Expert and learner review remain pending. For the drug-development landscape, see the plain-language payload summary.

References

1. Yamazaki et al., 2021 — a HER2 ADC carrying MMAE and MMAF outperformed co-administration of two single-payload ADCs in mouse models of HER2-heterogeneous, drug-resistant breast cancer.
2. Abel et al., 2023 — phase 1 trial of sacituzumab govitecan with the ATR inhibitor berzosertib in 12 patients; no dose-limiting toxicities.
3. Jossé et al., 2014 — a gene-silencing screen of nearly 7,000 genes identified ATR loss as synthetic lethal with camptothecin; ATR inhibitors sensitized cells to TOP1 inhibitors.
4. Li et al., 2025 — a TROP2 ADC carrying exatecan was synergistic with ATR inhibitors in pancreatic cancer cells; the ADC alone was active in xenografts.
5. Ravenstijn et al., 2026 — clinical pharmacology of dual-payload ADCs; none approved.
6. ClinicalTrials.gov: IBI3028 phase 1 — an EGFR and c-MET bispecific dual-payload conjugate in advanced solid tumors; recruiting, checked November 7, 2026.

Used in

• Read a new payload strategy
• Aiming a drug at a surface target